For Health Plans & Payers
Early detection. Better outcomes. Lower costs.
GeneSprout partners with health plans to bring actionable pediatric genetic screening to your members.
- CAP/CLIA certified laboratory
- Health navigation included
- Ongoing monitoring as science evolves
Population Health Impact
The case for early pediatric genetic screening.
- 53.5% Reduction in cancer deaths in universal screening of newborns Yeh et al, 2021
Proactive risk detection changes outcomes
When a condition is found before symptoms escalate, the clinical pathway is clearer and interventions are more effective. Earlier detection results in fewer late-stage diagnoses, less intenstive treatments, and the most appropriate treatment pathway.
- 5 to 30 years Avg time families search for answers Wu et al, 2020
Pediatric diagnostic odyssey costs are avoidable
Early identification shortens the cycle of unnecessary tests and specialist visits, whose combined costs often exceed GeneSprout’s. A negative genetic result can also eliminate the need for further testing and provide peace of mind to families.
- $80 K Avg savings per child
Real world evidence
The SAVES-Kids Health Economics study shows that genetic testing improves care and reduces healthcare costs by up to 61% in the year following testing for children with neurological conditions.
- 72% Parent adoption rate GUARDIAN study
Align with emerging standards for care
Health plans have a unique opportunity to redefine quality in pediatrics to early, actionable intervention. Pediatric genetic screening has proven feasible at scale, and GeneSprout is aligned with AAP guidelines for genetic screening.
What we offer
A partnership built around childhood outcomes and a return on investment.
GeneSprout offers health plans a clinically rigorous, operationally straightforward pathway to accessible, cutting edge pediatric genetic screening, health navigation and a financial return.
Comprehensive screening for 2,200+ actionable conditions
Whole exome and whole genome sequencing across cardiovascular, metabolic, neurological, and pharmacogenomic conditions — focused exclusively on findings where early knowledge changes care.
CAP/CLIA-certified laboratory
All screenings are processed in a CAP/CLIA-certified lab, meeting the same clinical standard as hospital labs
Family-friendly genetic report
Results are delivered via a secure, HIPAA-compliant portal in plain language and easily shared with their child's pediatrician.
Health navigation and family support
When a finding is identified, GeneSprout's health navigation team provides direct family support and expert guidance including a roadmap.
Ongoing monitoring as science evolves
Member value doesn't end at the initial result. As new research emerges, we review existing data and notify families of newly relevant findings.
Your brand. Our science.
GeneSprout's co-branding capabilities mean your members experience pediatric genetic screening as part of your program — building trust and delivering outcomes that matter to families.
How it works
Together, we can redefine pediatric care from reactive to proactive.
Connect with our team
Reach out to begin a partnership conversation. We'll learn about your population and how GeneSprout can best integrate into existing plan offerings.
Design your program
We work with your team to define how GeneSprout is offered to members — with flexibility to start with a targeted program for specific member cohorts and then scale.
Members access screening
Eligible members receive access to the GeneSprout program. The process is simple: the member orders a kit, it ships to their home, they perform a cheek swab, and return the sample by prepaid mail.
Results and navigation
Members receive family-friendly results in a secure, HIPAA-compliant portal. Where findings warrant it, GeneSprout's health navigation team provides direct family support including a roadmap.
Ongoing review and reporting
Plans receive de-identified operational and clinical reporting to measure program success and determine population health impact.
Real-world impact
What early detection actually changes.
Case Study
Wilson's Disease
A rare genetic disorder causing copper to accumulate in the liver, brain, and other organs. When caught early, Wilson's Disease is highly treatable. When missed, it causes progressive and irreversible organ damage.
1 in 30,000
children affected
Liam, age 10
Diagnosed after symptom onset
- Tremor and school decline; misdiagnosed for 18 months.
- Presented with jaundice and abnormal muscle contractions; hospitalized, lifelong meds.
- Father provides daily care to Liam; has increased medical expenses due to stress and anxiety related to caregiving
Julia, age 6
Identified through genetic screening
- Condition discovered by genetic screening
- Started zinc tablets ($1/day); liver enzymes normalized in 9 months
- Today, varsity soccer player with perfect school attendance
- CAP/CLIA certified laboratory
- HIPAA-compliant & SOC2
- Pediatrician led
- Ongoing science monitoring
Learn more
Explore what makes GeneSprout different.
Our Screening Science
Focus on actionable conditions in childhood
Whole exome and whole genome sequencing covering 2,200+ actionable conditions that parents and clinicians can do something about.
Health Navigation Solution
From finding to follow-through.
Our health navigation team supports families from the moment of a finding with clear next steps and a roadmap.
In the News
Pediatric genetics, covered.
The latest research, policy updates, and stories shaping the future of early childhood genetic screening.